Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 24Active not recruiting 13Not yet recruiting 3Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 2Other solid neoplasm 1

Conditions

Refractory or Relapsed Solid Tumors 1Prostatic Neoplasms 1Non-metastatic Castration-resistant Prostate Cancer 1

Interventions

Specimen Handling 60Magnetic Resonance Spectroscopy 43Carboplatin 33Cyclophosphamide 31Gemcitabine 28Biopsy 26Cisplatin 25pembrolizumab 24Bevacizumab 24Paclitaxel 23Injections 22Standard of Care 21Radiotherapy 21Drug Therapy 21Capecitabine 21fludarabine 20venetoclax 19Oxaliplatin 19toripalimab 17Nivolumab 17Interviews as Topic 17Dexamethasone 17Blood Specimen Collection 16anlotinib 15Radiosurgery 15tislelizumab 14Azacitidine 14cemiplimab 13Pemetrexed 13Irinotecan 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × darolutamide × 90 days × Clear all
NCT07620041 2026-06-02

QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

Qilu Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
48 enrolled
Other solid neoplasm

Refractory or Relapsed Solid Tumors

NCT07538843 2026-05-15

DARE

Bayer

Not yet recruiting
800 enrolled
Genitourinary

Non-metastatic Castration-resistant Prostate Cancer

NCT07476677 2026-03-17

ANDARP

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
60 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡